On The Pen GLP-1 News
On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.
On The Pen GLP-1 News
On The Pen Live Eps 67: Survodutide Trial Participant Tells All!
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
In this week’s episode of On The Pen Live, guest Scott Liberto of PlanetScott.com joins to discuss his experience in the Survodutide clinical trial.
Survodutide is an investigational dual agonist targeting both the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim in collaboration with Zealand Pharma. This novel drug is designed to treat obesity and metabolic dysfunction-associated steatohepatitis (MASH).
Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!
🤝 Visit Our Sponsors!
OTPLinks.com
Decoding GLP-1 Book
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen
Buy Here: https://amzn.to/3Dc66d4
MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:
Venmo: OnThePen
Ca$h App: ManOnMounjaro
BECOME A MEMBER:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join
👉 My Amazon Affiliate Store:
https://www.amazon.com/shop/manonthemounjaroonthepen
WATCH MORE!
📺 We're Live M/W/F at 11 central: onthepen.tv
📲 Contact Me: dave@onthepen.com
Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.
